Greater Philadelphia’s cell and gene therapy sector will be well represented next month at the Cell & Gene Meeting on the Mesa in Carlsbad, CA, as the hybrid conference gathers industry leaders to advance cutting-edge research into cures. Representatives of nine area companies are participating in the October 12-14 meeting, which will attract 1,200 attendees, and is organized by the Alliance for Regenerative Medicine.
Participating companies from the Greater Philadelphia region include: Adaptimmune, Amicus Therapeutics, Cabaletta Bio, Carisma, Passage Bio, SwanBio Therapeutics, and Tmunity Therapeutics. Leaders from those companies will be sharing technical and clinical achievements during in-person and pre-recorded presentations. In addition, AmerisourceBergen, Amicus Therapeutics, and the Center for Breakthrough Medicines at Discovery Labs are sponsors.
Usman “Oz” Azam, M.D., president and CEO of Tmunity Therapeutics, is chairing a plenary session on “Cellular Immunotherapy Pioneers – Liquid vs. Solid Tumor Strategies,” at 9:15 a.m. on Oct. 12. Tmunity Therapeutics is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy to patients with devastating diseases.
Jill Quigley, chief operating officer at Passage Bio, will present in-person at 2:45 p.m. on Oct. 12. Passage Bio’s mission is to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases.
Jeff Castelli, chief development officer at biotechnology company Amicus Therapeutics, will present in-person at 5:00 p.m. on Oct. 12. Amicus Therapeutics is focused on delivering novel medicines for people living with rare metabolic diseases.
Other company presentations will be offered through the virtual on-demand platform from the following Greater Philadelphia region industry leaders:
John Lunger, chief patient supply officer at Adaptimmune, a leader in T cell therapy that has clinical trials ongoing for three wholly owned SPEAR T cells in multiple solid tumor indications.
Steven Nichtberger, M.D., president, CEO, and co-founder of clinical-stage biotechnology company Cabaletta Bio; which is focused on the discovery and development of engineered T cell therapies, and exploring their potential for patients with B cell-mediated autoimmune diseases.
Steven Kelly, CEO, Carisma, a clinical-stage biopharmaceutical company developing a differentiated and proprietary cell therapy platform focused on engineered microphages, cells that play a crucial role in both the innate and adaptive immune response.
Karen Kozarsky, Ph.D., is chief science officer at SwanBio Therapeutics, the premier CNS spinal cord-focused AAV gene therapy company, bringing treatments to people with genetically defined neurological conditions.